A Science|Business public webcast, in partnership with Novartis / REPLAY NOW AVAILABLE
COVID-19 has shattered many conventions about how healthcare and medical products can be designed and delivered. It has inspired Europe and its stakeholders – research institutions, regulatory bodies, public health agencies, industry, and policy institutions – to collaborate at unprecedented speed to fight the pandemic. And indeed, since last summer European citizens have been witnessing more effective and streamlined ways for new medicines and devices to access the market while complying with quality standards, ensuring positive patient-reported outcomes (PRO).
The insights learned from this experience are already inspiring a re-think of existing systems, with the European Commission pushing ahead with several ambitious initiatives and global partnerships to prepare for the future – among them the EU4Health initiative, a new agency for emergency response and preparedness (HERA), a European Health Data Space, and the COVAX facility.
However, the crisis has also deprived millions of citizens of access to care and treatments; in parallel, it has blown holes in traditional health budgets. Europe promises to “build back better” in the recovery phase – but it will have to address an enormous backlog of population health needs during what is likely to be an extended economic downturn. In this regard, the quality, value and impact of health treatments and products will have paramount importance for years to come.
On May 5, Science|Business will bring together two high-level panels to discuss the future challenges of adapting processes and models to enable fast, equitable and sustainable access to treatments to meet the needs of patients across Europe. Among the questions this webcast will seek to address:
- Which lessons can be drawn from the development of medicines related to COVID-19 and adapted to a far broader range of therapeutics and products, ensuring their rapid availability and distribution to patients across Europe?
- What can value-and-outcome-based approaches (VOBHC) and patient-reported outcomes (PRO) be relevant to shape post-COVID healthcare systems?
- How can accelerated access to treatments serve as a critical connecting point between Europe's health, research and industrial strategies?
- How can European healthcare companies amplify their impact and deliver greater sustainability in alignment with EU strategy and expectations?
15:00 - NETWORKING
15:30 - WELCOME & INTRODUCTION
15:35 - SESSION I – Accelerating HCS transformation: Can Europe seize this unique window of opportunity?
An interactive debate, focused on the latest political developments at European level.
- Andrzej Jan Rys, Director, Health systems, medical products and innovation, DG SANTE, European Commission
- Cristian Silviu Bușoi, Member, European Parliament
16:05 - NETWORKING BREAK
16:15 - SESSION II – Accelerating access for patients: Can the COVID approach be replicated across systems and conditions?
An interactive panel discussion, focused on the replicability and scalability of pandemic response blueprints, and/or new public-private reimbursement models.
- Klemen Grošelj, Member, European Parliament
- Francesca Colombo, Head, Health Division, OECD
- Momir Radulovic, Executive Director, Agency for Medicinal Products and Medical Devices of the Republic of Slovenia
- Janneke van der Kamp, Head, Region Europe, Novartis
17:05 - END